Prostatype Genomics AB Logo

Prostatype Genomics AB

Provides a genetic test to assess prostate cancer aggressiveness and guide treatment choices.

PROGEN | ST

Overview

Corporate Details

ISIN(s):
SE0022574554 (+2 more)
LEI:
549300JO6MPCGPVHVU91
Country:
Sweden
Address:
Gustav III:s Boulevard 34, 169 73 Solna
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Prostatype Genomics AB specializes in the development, manufacturing, and marketing of the prognostic genetic test, Prostatype®. The test is designed to provide a comprehensive assessment of the aggressiveness of diagnosed prostate cancer, particularly for patients with localized disease. It serves as a decision-making tool for clinicians and patients to help determine appropriate treatment strategies. The Prostatype® system uses existing biopsy tissue to analyze the expression of three key genes. This genetic data is combined with standard clinical parameters (PSA, Gleason Score, Tumor Stage) to calculate a proprietary P-score, which quantifies the risk of cancer mortality. By offering a more precise prognosis, the test aims to minimize both over- and under-treatment, thereby improving patient quality of life and saving healthcare resources.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Prostatype Genomics AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Prostatype Genomics AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Prostatype Genomics AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Stayble Therapeutics AB Logo
Develops an injectable drug for lumbar disc herniation pain as an alternative to surgery.
Sweden
STABL
STCUBE Logo
Develops first-in-class immunotherapies targeting BTN1A1 for treatment-resistant cancers.
South Korea
052020
StemRIM Inc. Logo
Developing regenerative medicines that use the body's own stem cells to treat intractable diseases.
Japan
4599
Surrozen, Inc./DE Logo
Develops regenerative antibodies modulating the Wnt pathway to repair tissues and restore organs.
United States of America
SRZN
SyntekaBio,Inc. Logo
AI drug discovery platform accelerating R&D with supercomputing, SaaS, and pre-made candidates.
South Korea
226330
Tango Therapeutics, Inc. Logo
Developing precision oncology therapies for genetically-defined patients via synthetic lethality.
United States of America
TNGX
Taysha Gene Therapies, Inc. Logo
Developing AAV-based gene therapies for rare, severe monogenic diseases of the central nervous system.
United States of America
TSHA
Tectonic Therapeutic, Inc. Logo
Developing biologic therapies that modulate GPCRs for diseases with unmet needs.
United States of America
TECX
Telomir Pharmaceuticals, Inc. Logo
Developing an oral small molecule to reverse aging and treat age-related diseases.
United States of America
TELO
Tempest Therapeutics, Inc. Logo
Clinical-stage oncology company developing oral small molecule therapeutics to treat cancer.
United States of America
TPST

Talk to a Data Expert

Have a question? We'll get back to you promptly.